TAVI and Hypertrophic Cardiomyopathy: An Increasingly Common Association

Stenosis is a common disease affecting 5% of the elderly population. It is associated with hospitalizations, poor quality of life, and mortality. 

angulación aórtica post TAVR

The association between severe aortic stenosis (SAS) and hypertrophic cardiomyopathy (HCM) is increasingly frequent.

Currently, the available information on this scenario is limited and comes mainly from small registries or the analysis conducted by Mhanna et al., who compared transcatheter aortic valve replacement (TAVR) with surgery in this patient group. The results showed that TAVR was associated with lower in-hospital mortality, fewer complications, reduced need for vasoactive drugs, lower incidence of cardiogenic shock, and a shorter hospital stay.

Researchers conducted a meta-analysis including 1095 patients with SAS and HCM. 

Patients with HCM experienced the following:

  • Five times higher mortality rates (odds ratio [OR] 5.79; 95% confidence interval [CI]: 3.38-9.91, p <0.0001; I² = 85%).
  • Four times higher incidence of cardiogenic shock (OR 4.55; 95% CI: 3.40-6.08, p <0.0001; I² = 48%).
  • Higher incidence of vascular complications (OR 2.10; 95% CI: 1.27-3.47, p = 0.004; I² = 14%).
  • Increased renal failure (OR 1.80; 95% CI: 1.36-2.40, p <0.0001; I² = 64%).
  • Greater risk of aortic dissection (OR 4.95; 95% CI: 3.17-7.74, p <0.0001; I² = 0%).

Read also: Mechanical Circulatory Support in Complex Anatomies and Severe Deterioration of Left Ventricular Function.

There were no significant differences in the incidence of atrioventricular (A-V) block, need for permanent pacemaker, or bleeding events.

Conclusion

In patients with severe aortic stenosis and associated hypertrophic cardiomyopathy, TAVR was linked to a higher incidence of mortality, cardiogenic shock, aortic dissection, vascular complications, renal failure, and an increased need for mechanical ventilation compared to those without hypertrophic cardiomyopathy.

Original Title: Transcatheter Aortic Valve Replacement in Hypertrophic Cardiomyopathy: A Systematic Review and Meta‐ Analysis

Reference: Ashraf Ahmed, et al. Catheterization and Cardiovascular Interventions, 2025; 105:754–760 https://doi.org/10.1002/ccd.31367


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...